Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shingo Matsumoto
Institution:
National Cancer Center Hospital East
Observed institution:
National Cancer Center Hospital East
ORCID:
0000-0001-9627-5401
Observed ORCID:
0000-0001-9627-5401
OpenAlex ID:
A5081915644
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2022
·
Akira Sugimoto
, Shingo Matsumoto
, et al.
·
Clinical Cancer Research
·
79
Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
2024
·
Yuji Uehara
, Hiroki Izumi
, et al.
·
JTO Clinical and Research Reports
·
5
PDF
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
2025
·
Batel Blechter
, Xiaoyu Wang
, et al.
·
JNCI Journal of the National Cancer Institute
·
4
PDF
Clinical, genomic, and pathological features and therapeutic outcomes of non-small cell lung cancer with MTAP-loss.
2025
·
Hibiki Udagawa
, Shingo Matsumoto
, et al.
·
Journal of Clinical Oncology
·
4
Abstract 7198: Preclinical efficacy of the combination of MEK inhibitor plus KRAS G12D inhibitor for non-small cell lung cancer with KRAS G12D
2025
·
Yu Tanaka
, Mirai Tsukuda
, et al.
·
Cancer Research
·
3
Suitability of frozen cell pellets from cytology specimens for the A moy 9‐in‐1 assay in patients with non‐small cell lung cancer
2024
·
Hiroaki Kodama
, Haruyasu Murakami
, et al.
·
Thoracic Cancer
·
3
A simplified scoring system for predicting treatment response in limited-stage small-cell lung cancer (EAST score)
2024
·
Yu Ito
, Yoshitaka Zenke
, et al.
·
Future Oncology
·
2
PDF
Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP).
2024
·
Shigeki Umemura
, Chih-Hsi Kuo
, et al.
·
Journal of Clinical Oncology
·
2
KRAS G12V mutation as an acquired resistance mechanism after treatment with dabrafenib and trametinib in non-small cell lung cancer harbouring the BRAF V600E mutation: a case report
2022
·
Hajime Oi
, Kiyotaka Yoh
, et al.
·
Precision Cancer Medicine
·
2
Prognostic impact of actionable driver alterations and efficacy of targeted therapy in lung squamous cell carcinoma: A large-scale nationwide genomic screening (LC-SCRUM-Asia).
2026
·
Tetsuya Sakai
, Hiroki Izumi
, et al.
·
Journal of Clinical Oncology
·
1
Initial results of a screening trial for evaluating oncogenic drivers in Japanese patients with surgically resected early-stage non-small cell lung cancer: LC-SCRUM-Advantage.
2025
·
Yuki Matsumura
, Kiyotaka Yoh
, et al.
·
Journal of Clinical Oncology
·
1
Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)
2025
·
Yuji Uehara
, Hiroki Izumi
, et al.
·
Lung Cancer
·
1
PDF
Large-scale comparative analysis of clinico-genomic characteristics, treatment outcomes and resistant mechanisms of ALK/ROS1/RET-rearranged non-small cell lung cancer (NSCLC) in a nationwide genomic screening project (LC-SCRUM-Asia/TRY).
2023
·
Yosuke Kagawa
, Yuji Shibata
, et al.
·
Journal of Clinical Oncology
·
1
Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023
·
Akira Sugimoto
, Shingo Matsumoto
, et al.
·
1
Co-occurring gene alterations associated with efficacy of osimertinib in EGFR-mutated lung cancer: Based on a large-scale genomic screening project (LC-SCRUM-Asia).
2022
·
Yuji Shibata
, Shingo Matsumoto
, et al.
·
Journal of Clinical Oncology
·
1
Figure S1 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Figure S10 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Figure S5 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Figure S8 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Figure S3 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Figure 6 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Figure 4 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Figure S7 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Figure 1 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Data from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
2026
·
Yves A. Millet
, Alexander I. Spira
, et al.
Show more works
View as search
Works count:
55
Citation count:
110
H-index:
4
I10-index:
1
Year
Topic
Type